Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Latest news

Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.

Subscribe to our mailing list

13 Oct 2021
Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
  • THR-687 is a potent pan-RGD integrin antagonist holding potential as a next
    • ...
11 Oct 2021
Clinical update; THR-149
Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Specialists (ASRS) Annual Scientific Meeting
  • Patients in the highest dose group achieved an overall mean 6.1 letter improvement in
    • ...
5 Oct 2021
OXURION to Present at the Lytham Partners Fall 2021 Investor Conference

Leuven, BELGIUM, Boston, MA, US – 5 October, 2021 – 08.00 AM CET –...

30 Sep 2021
Inside information, Clinical update, THR-149
OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Decision taken to move the highest dose of THR-149 (0.13mg) into Part...

9 Sep 2021
Company; THR-149; THR-687; Investors
Oxurion NV Business & Financial Update – H1 2021

Highlights

...

8 Sep 2021
THR-149; own; thr-687
OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress

Leuven, BE, Boston, MA, US – September 8  – 08.00 AM CET   ...

17 Aug 2021
THR-687; own
Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal

Leuven, BE, Boston, MA, US – August 17, 2021 – 08.00 AM CET –...

Archive

Media contact

Oxurion is committed and engaged to communicate openly with all of its stakeholders. For any media enquiries, comments or questions about Oxurion, please contact our Investor Relations & Corporate Communications team:

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310

Info@oxurion.com